Skip to Main Content

Paper Details

Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.
Kidney Int
59
2019
ESRD, Gynecomastia, Hyperkalemia, Spironolactone, end-stage renal disease, hyperkalemia, hypotension, participants, patient, patients, potassium, spironolactone
Author NameAffiliation
Jonathan HimmelfarbKidney Research Institute, University of Washington
Jonathan HimmelfarbKidney Research Institute, University of Washington
Talat Alp Ikizlerand Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center
Adriana M Hungand Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center
  • 1 - 4

Datasets

Release 1.2